[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, MB Beasley, DA Chitale… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: a systematic review and meta-analysis
LY Chen, MA Molina-Vila, SY Ruan, KY Su, WY Liao… - Lung cancer, 2016 - Elsevier
Objective Previous studies have indicated that EGFR exon 19 deletions in non-small cell
lung cancer (NSCLC) are associated with better outcomes to tyrosine kinase inhibitors …
lung cancer (NSCLC) are associated with better outcomes to tyrosine kinase inhibitors …
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of …
Purpose Programmed cell death-1 (PD-1)/programmed cell death-ligand-1 (PD-L1) pathway-
targeted immunotherapy has beneficial therapeutic effects in pulmonary squamous cell …
targeted immunotherapy has beneficial therapeutic effects in pulmonary squamous cell …
Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
JN Jakobsen, JB Sørensen - Cancer chemotherapy and pharmacology, 2012 - Springer
Introduction Biomarker expression is increasingly being used to customize treatment in non-
small cell lung cancer (NSCLC). The choice of systemic treatment usually depends on …
small cell lung cancer (NSCLC). The choice of systemic treatment usually depends on …
Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
X Hong, MT Hsieh, TY Tseng, HY Lin, HC Chang… - Journal of Biological …, 2023 - ASBMB
Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) patients
often respond to EGFR tyrosine kinase inhibitors (TKIs) initially but eventually develop …
often respond to EGFR tyrosine kinase inhibitors (TKIs) initially but eventually develop …
Micro RNA‐133b inhibits the growth of non‐small‐cell lung cancer by targeting the epidermal growth factor receptor
L Liu, X Shao, W Gao, Z Zhang, P Liu, R Wang… - The FEBS …, 2012 - Wiley Online Library
Both the deregulation of microRNAs and epidermal growth factor receptor (EGFR) are
emerging as important factors in non‐small‐cell lung cancer (NSCLC). Here, miR‐133b was …
emerging as important factors in non‐small‐cell lung cancer (NSCLC). Here, miR‐133b was …
Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
J Chmielecki, JS Ross, K Wang, GM Frampton… - The …, 2015 - academic.oup.com
Abstract Background. Targeted ERBB2/HER2 inhibitors are approved by the US Food and
Drug Administration for the treatment of breast, gastric, and esophageal cancers that …
Drug Administration for the treatment of breast, gastric, and esophageal cancers that …
The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis
L Qiu, Y Xu, H Xu, B Yu - BMC cancer, 2022 - Springer
Background The CXC chemokine receptor 4 (CXCR4) has been suggested to play an
important role in several types of cancers and is related to biological behaviors connected …
important role in several types of cancers and is related to biological behaviors connected …
EGFR exon 20 insertion/duplication mutations characterize fibrous hamartoma of infancy
JY Park, C Cohen, D Lopez, E Ramos… - The American journal …, 2016 - journals.lww.com
Fibrous hamartoma of infancy (FHI) is a benign mesenchymal tumor histologically
characterized by a mixture of intersecting fascicles of fibroblasts/myofibroblasts in …
characterized by a mixture of intersecting fascicles of fibroblasts/myofibroblasts in …
Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients
L Shan, Z Wang, L Guo, H Sun, T Qiu, Y Ling, W Li, L Li… - Lung Cancer, 2015 - Elsevier
Objectives Tumor heterogeneity, which causes different EGFR mutation abundance, is
believed to be responsible for varied progression-free survival (PFS) in lung …
believed to be responsible for varied progression-free survival (PFS) in lung …